Drug intelligence / Profile preview

LDN-081

Development stage: Preclinical
Lead developer: Ladon Therapeutics
Modality: Peptides
Administration: Oral

Overview

LDN-081 is an investigational oral peptide therapeutic being developed by Ladon Therapeutics. It belongs to a first-in-class category of A3SMO-based therapeutics designed to target autoimmune diseases, fibrosis, and obesity. The drug utilizes a peptide-based modality delivered orally to modulate the A3SMO target, which is associated with anti-inflammatory and anti-fibrotic biological pathways. While specific clinical data is limited, it is part of a broader pipeline of A3SMO-targeted agents aimed at addressing metabolic and inflammatory conditions.

Beyond the preview

Go deeper on LDN-081.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LDN-081.

Explore the full profile